{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:41:58Z","timestamp":1781343718702,"version":"3.54.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jacl.2022.05.067","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T18:50:20Z","timestamp":1654368620000},"page":"389-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT"],"prefix":"10.1016","volume":"16","author":[{"given":"Prakriti","family":"Gaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-1852","authenticated-orcid":false,"given":"R. Preston","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1679-2095","authenticated-orcid":false,"given":"Michael","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph. Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Boden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2022.05.067_bib0001","unstructured":"Hill MF., Bordoni B. Hyperlipidemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. Available at: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559182\/. Accessed February 15, 2022."},{"key":"10.1016\/j.jacl.2022.05.067_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015801","article-title":"Association of hypertriglyceridemia with all-cause mortality and atherosclerotic cardiovascular events in a low-risk Italian population: the TG-REAL retrospective cohort analysis","volume":"9","author":"Arca","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2022.05.067_bib0003","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet N Am Ed"},{"key":"10.1016\/j.jacl.2022.05.067_bib0004","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2014.02.025","article-title":"Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma","volume":"234","author":"Nishio","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2022.05.067_bib0005","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jjcc.2013.12.008","article-title":"Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study)-rationale and design","volume":"64","author":"Watanabe","year":"2014","journal-title":"J Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0006","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jjcc.2017.07.007","article-title":"A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins","volume":"70","author":"Watanabe","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0007","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/ehjcvp\/pvaa118","article-title":"REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results","volume":"7","author":"Olshansky","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacl.2022.05.067_bib0008","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2022.05.067_bib0009","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2022.05.067_bib0010","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/cvr\/cvaa184","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results","volume":"117","author":"Budoff","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacl.2022.05.067_bib0011","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the Omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100106","article-title":"EPA and DHA containing phospholipids have contrasting effects on membrane structure","volume":"62","author":"Sherratt","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2022.05.067_bib0013","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.2021.0824","article-title":"Omega-3 fatty acids effect on major cardiovascular events in patients at high cardiovascular risk","volume":"325","author":"Olshansky","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2022.05.067_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.plefa.2021.102337","article-title":"Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability","volume":"173","author":"Sherratt","year":"2021","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.jacl.2022.05.067_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103040","article-title":"A Randomized trial of icosapent ethyl in ambulatory patients with COVID-19","author":"Kosmopoulos","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jacl.2022.05.067_bib0016","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_sbref0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.pcad.2021.08.003","article-title":"The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization","author":"Bhatt","year":"2021","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2022.05.067_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.05.067_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024999","article-title":"Impact of icosapent ethyl on cardiovascular risk reduction in patients with heart failure in REDUCE-IT","volume":"11","author":"Selvaraj","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2022.05.067_bib0020","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/eurheartj\/ehz778","article-title":"Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics","volume":"41","author":"Boden","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2022.05.067_bib0021","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jacc.2021.08.009","article-title":"Comparative reductions in investigator-reported and adjudicated ischemic events in REDUCE-IT","volume":"78","author":"Gaba","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0022","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jacc.2019.08.007","article-title":"Reply: ischemic event reduction and triglycerides","volume":"74","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0023","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2022.05.067_bib0024","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2022.05.067_bib0025","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/eurheartj\/ehz179","article-title":"REDUCE-IT: residual cardiovascular risk in statin-treated patients with elevated triglycerides: now we can REDUCE-IT!","volume":"40","author":"Bhatt","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2022.05.067_bib0026","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","article-title":"Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles","volume":"74","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0027","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0028","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2022.05.067_bib0029","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.amjmed.2021.03.014","article-title":"Mechanistic insights from REDUCE-IT STRENGTHen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction","volume":"134","author":"Mason","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2022.05.067_bib0030","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"The ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.05.067_bib0031","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2022.05.067_bib0032","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.05.067_bib0033","article-title":"Assessment of the role of niacin in managing cardiovascular disease outcomes: a systematic review and meta-analysis","volume":"2","author":"D'Andrea","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacl.2022.05.067_bib0034","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.biopha.2018.04.118","article-title":"Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin","volume":"103","author":"Mason","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jacl.2022.05.067_bib0035","article-title":"Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro","volume":"1862","author":"Sherratt","year":"2020","journal-title":"Biochim Biophys Acta BBA Biomembr"},{"key":"10.1016\/j.jacl.2022.05.067_bib0036","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/01.CIR.79.4.733","article-title":"Circadian variation and triggers of onset of acute cardiovascular disease","volume":"79","author":"Muller","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2022.05.067_bib0037","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A prospective natural-history study of coronary atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.05.067_bib0038","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jacc.2020.09.547","article-title":"Percutaneous coronary intervention for vulnerable coronary atherosclerotic plaque","volume":"76","author":"Stone","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0039","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.jacc.2019.07.062","article-title":"From detecting the vulnerable plaque to managing the vulnerable patient: JACC state-of-the-art review","volume":"74","author":"Arbab-Zadeh","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0040","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jacc.2021.11.005","article-title":"Consistency of benefit of icosapent ethyl by background statin type in REDUCE-IT","volume":"79","author":"Singh","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0041","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.3341","article-title":"REDUCE-IT: outcomes by baseline statin type","volume":"41","author":"Bhatt","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2022.05.067_bib0042","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2022.02.035","article-title":"Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction","volume":"79","author":"Gaba","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0043","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jacc.2022.03.001","article-title":"Optimizing dyslipidemic cardiovascular residual risk reduction with icosapent ethyl in post-MI patients","volume":"79","author":"Boden","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0044","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCULATIONAHA.120.050276","article-title":"Reduction in revascularization with icosapent ethyl","volume":"143","author":"Peterson","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2022.05.067_bib0045","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.05.067_bib0046","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022937","article-title":"Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention\u2014 insights from REDUCE-IT PCI","volume":"11","author":"Peterson","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2022.05.067_bib0047","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.05.067_bib0048","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jacc.2017.07.001","article-title":"Primary prevention of cardiovascular disease in diabetes mellitus","volume":"70","author":"Newman","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0049","unstructured":"Bhatt DL, Brinton EA, Miller M. Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES. 2020. Available at: ePoster # 627_PDF, EASD 2020, https:\/\/www.easd.org\/virtualmeeting\/home.html#!resources\/substantial-cardiovascular-benefit-from-icosapent-ethyl-in-patients-with-diabetes-reduce-it-diabetes-49f795f6-26cb-4516-b477-3ca7e3cdfa2e."},{"key":"10.1016\/j.jacl.2022.05.067_bib0050","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1161\/ATVBAHA.111.233049","article-title":"The complex metabolic mechanisms relating obesity to hypertriglyceridemia","volume":"31","author":"Eckel","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0051","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","article-title":"Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction","volume":"143","author":"Kalstad","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2022.05.067_bib0052","doi-asserted-by":"crossref","first-page":"J34","DOI":"10.1093\/eurheartj\/suaa117","article-title":"Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies","volume":"22","author":"Olshansky","year":"2020","journal-title":"Eur Heart J Suppl J Eur Soc Cardiol."},{"key":"10.1016\/j.jacl.2022.05.067_bib0053","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/cvr\/cvz329","article-title":"Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography","volume":"116","author":"Lakshmanan","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacl.2022.05.067_bib0054","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1093\/eurheartj\/ehab760","article-title":"The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl","volume":"42","author":"Steg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2022.05.067_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101110","article-title":"Meta-analysis of contemporary trials of Omega-3 fatty acids containing both eicosapentaenoic and docosahexaenoic acids","volume":"39","author":"Khan","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jacl.2022.05.067_sbref0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100997","article-title":"Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis","volume":"38","author":"Khan","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jacl.2022.05.067_bib0057","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11892-020-01343-7","article-title":"The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction","volume":"20","author":"Wang","year":"2020","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jacl.2022.05.067_bib0058","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2217\/fca-2020-0106","article-title":"Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction","volume":"17","author":"Boden","year":"2021","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0059","first-page":"S125","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142021","volume":"44","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2022.05.067_bib0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3032","article-title":"Adherence to guideline medication recommendations to prevent atherosclerotic cardiovascular disease progression among adults with prior myocardial infarction","volume":"3","author":"Arnold","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacl.2022.05.067_bib0061","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0062","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","article-title":"Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association","volume":"141","author":"Arnold","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2022.05.067_bib0063","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2019.01.016","article-title":"Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease","volume":"73","author":"Picard","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.067_bib0064","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.48172","article-title":"Cost-effectiveness of icosapent ethyl for high-risk patients with hypertriglyceridemia despite statin treatment","volume":"5","author":"Weintraub","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422001660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422001660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:36:48Z","timestamp":1761831408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287422001660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1933287422001660"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2022.05.067","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2022.05.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}